Table 1.
Sample characteristics of (A) immunoprecipitation–MS cohort and (B) validation cohort
| A | Benign | Borderline | Malignant | Grade | FIGO Stage | |||
|---|---|---|---|---|---|---|---|---|
| Histology | G1/G2/G3 | I | II | III | IV | |||
| n = 38 (%) | n = 22 (58) | n = 0 | n = 16 (42) | |||||
| Simple | 5 | |||||||
| Stromal | 2 | |||||||
| Dermoid | 2 | |||||||
| Endometrioma | 2 | |||||||
| Serous | 7 | 11 | 1, 5, 5 | 4 | 1 | 6 | ||
| Endometrioid | 2 | 2, 0, 0 | 2 | |||||
| Clear cell | 1 | 1, 0, 0 | 1 | |||||
| Undiff | 2 | 1, 0, 0 | 1 | 1 |
| B | Benign | Borderline | Malignant | Grade | FIGO Stage | |||
|---|---|---|---|---|---|---|---|---|
| Mean age (range) | 60 (16–88) | 51 (31–85) | 61 (28–88) | |||||
| Histology | G1/G2/G3 | I | II | III | IV | |||
| n = 256 (%) | n = 156 (61) | n = 22 (9) | n = 78 (30) | 27/17/27 | n = 32 (41) | n = 7 (9) | n = 36 (46) | n = 4 (4) |
| Simple | 42 (27) | |||||||
| Stromal | 11 (7) | |||||||
| Endometrioma | 6 (4) | |||||||
| Hemorrhagic | 1 (1) | |||||||
| Dermoid | 8 (5) | 1 (1) | 0, 0, 1 | 1 | ||||
| Serous | 54 (35) | 12 (54) | 48 (61) | 13, 13, 22 | 15 | 4 | 27 | 2 |
| Mucinous | 34 (22) | 9 (41) | 7 (9) | 6, 1, 0 | 4 | 1 | 1 | 1 |
| Endometrioid | 1 (5) | 9 (12) | 4, 2, 3 | 5 | 1 | 3 | ||
| Clear cell | 6 (8) | 4, 1, 1 | 4 | 2 | ||||
| Undiff | 4 (5) | 1 | 3 | |||||
| Granulosa cell | 3 (4) | 3 |
G1, highly; G2, moderately; G3, poorly differentiated.